Michael May

20/20 Vision Centers, Inc. provides lasik surgery services. It offers refractive laser surgery that treats nearsightedness, farsightedness and astigmatism with incisions. It uses technology such as Nidek and Visx Star S3 Laser, Orbscan, and Hansatome Microkeratome. The company is headquartered in Murray, UT.

Rimon Therapeutics Ltd. develops and markets pharmaceutical products. The company was founded by Michael May and is headquartered in Mississauga, Canada.

Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.

The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada.

AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its product pipeline includes AGEX-VASC1, AGEX-BAT1, and AGEX-iTR1547. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.

ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013.